Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Transcriptional control of brown adipocyte differentiation and function by NFIA: recent perspectives on deciphering metabolic diseases

Hiraike Y.

Narrative Review on Type 2 Diabetes, published in J Biochem (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Biochem (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40581369
PMCID
PMC12372464
DOI
10.1093/jb/mvaf038
Citations
2

Abstract (original English)

Brown adipocytes dissipate chemical energy as heat and confer protection against type 2 diabetes and obesity. Nuclear factor I-A (NFIA) is a transcription factor that orchestrates the brown fat gene programme by activating cell type-specific enhancers and facilitating the genomic binding of PPARγ, the master regulator of adipogenesis, to these enhancers. NFIA promotes mitochondrial oxidative phosphorylation and thermogenesis, while reciprocally suppressing adipose tissue inflammation, thereby contributing to the maintenance of glucose and body weight homeostasis in mice. Here the author provides an overview of the identification of NFIA as a pivotal regulator of brown adipocyte biology, elucidates its underlying mechanisms of action, examines its implications for systemic metabolism and outlines future perspectives for research in this field.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMetabolic DiseasesCell DifferentiationTranscription, GeneticThermogenesisAdipogenesisNFI Transcription FactorsAdipose Tissue, BrownAdipocytes, Brown

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research